Search results
Showing 166 to 180 of 381 results for lung cancer
Awaiting development Reference number: GID-TA11965 Expected publication date: TBC
Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.
Discontinued Reference number: GID-TAG422
Awaiting development Reference number: GID-TA11499 Expected publication date: TBC
Awaiting development Reference number: GID-TA11967 Expected publication date: TBC
Awaiting development Reference number: GID-TA11747 Expected publication date: 14 April 2027
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development Reference number: GID-TA10900 Expected publication date: TBC
Awaiting development Reference number: GID-TA11594 Expected publication date: TBC
condition Cancer Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer? Medicines to reduce the...
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
Discontinued Reference number: GID-TA10105
Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]
Discontinued Reference number: GID-TA10546
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]
Discontinued Reference number: GID-TA10212
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
Discontinued Reference number: GID-TA10158